The present disclosure is directed to novel derivatives of terpenes, particularly derivatives of terpene alcohols, and methods of making them, compositions comprising them, and methods for using them.

The present application relates to a compound of the following formula (I)

##STR00001## in which —R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent independently of each other H or a (C.sub.1-C.sub.30) alkyl group, the total sum of the number of carbon atoms of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 being equal to 6+4x, x being a whole number of between 1 and 6, provided that: at most two of the groups R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H, R.sup.5 represents H, OR, or NR′R″ R, R′ and R″, identical or different, represent H, a (C1-C10) alkyl group, at least one of groups R.sup.1, R.sup.2, R.sup.3 or R.sup.4 comprises or is a tertiobutyl group. (I) the method for preparing same and the uses thereof as a plasticising lubricant, surfactant or in a cosmetic composition.

The present application relates to a compound of the following formula (I)

##STR00001## in which —R.sup.1, R.sup.2, R.sup.3 and R.sup.4 represent independently of each other H or a (C.sub.1-C.sub.30) alkyl group, the total sum of the number of carbon atoms of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 being equal to 6+4x, x being a whole number of between 1 and 6, provided that: at most two of the groups R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are H, R.sup.5 represents H, OR, or NR′R″ R, R′ and R″, identical or different, represent H, a (C1-C10) alkyl group, at least one of groups R.sup.1, R.sup.2, R.sup.3 or R.sup.4 comprises or is a tertiobutyl group. (I) the method for preparing same and the uses thereof as a plasticising lubricant, surfactant or in a cosmetic composition.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein le is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein le is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein le is a linear or branched C.sub.9-C.sub.33 alkyl or a linear or branched C.sub.9-C.sub.33 alkenyl with 1 to 4 double bonds; R.sup.2 is a linear or branched C.sub.9-C.sub.19 alkyl or a linear or branched C.sub.9-C.sub.19 alkenyl with 1 to 4 double bonds; and an ophthalmologically acceptable carrier.

The present invention relates to a process for preparing a mixture of cetylated fatty acids and a system for carrying out said process. Furthermore, the present invention relates to a composition comprising, or alternatively, consisting of said mixture of cetylated fatty acids. Finally, the present invention relates to said composition for use in the treatment and/or prevention of: (i) rheumatoid arthritis of inflammatory and non-inflammatory origin, in particular osteoarthritis; (ii) other inflammatory joint conditions; (iii) psoriasis, lupus, periodontal diseases or cardiovascular or heart diseases; (iv) all post-traumatic osteoarticular pathologies including sports injuries; (v) all degenerative joint pathologies (arthrosis, gonarthrosis, coxarthrosis, etc.), and (vi) inflammatory-traumatic tendon and muscular conditions. Furthermore, it is envisaged that the composition of the present invention be used in the treatment and/or prevention of the above-mentioned pathologies and disorders (i)-(vi) in association with a rehabilitative therapy. The composition comprising said mixture is formulated in a pharmaceutical form for oral use (novel food, supplement or medical device), i.e. in the form of a pill, pastille, capsule, tablet, granules, dispersible powder, syrup, solution or sprayable solution; for topical use, i.e. in the form of a cream, unguent, ointment, gel or spray to be used as such for application on the skin, or else for transdermal use in the form of a patch.

The present invention relates to a process for preparing a mixture of cetylated fatty acids and a system for carrying out said process. Furthermore, the present invention relates to a composition comprising, or alternatively, consisting of said mixture of cetylated fatty acids. Finally, the present invention relates to said composition for use in the treatment and/or prevention of: (i) rheumatoid arthritis of inflammatory and non-inflammatory origin, in particular osteoarthritis; (ii) other inflammatory joint conditions; (iii) psoriasis, lupus, periodontal diseases or cardiovascular or heart diseases; (iv) all post-traumatic osteoarticular pathologies including sports injuries; (v) all degenerative joint pathologies (arthrosis, gonarthrosis, coxarthrosis, etc.), and (vi) inflammatory-traumatic tendon and muscular conditions. Furthermore, it is envisaged that the composition of the present invention be used in the treatment and/or prevention of the above-mentioned pathologies and disorders (i)-(vi) in association with a rehabilitative therapy. The composition comprising said mixture is formulated in a pharmaceutical form for oral use (novel food, supplement or medical device), i.e. in the form of a pill, pastille, capsule, tablet, granules, dispersible powder, syrup, solution or sprayable solution; for topical use, i.e. in the form of a cream, unguent, ointment, gel or spray to be used as such for application on the skin, or else for transdermal use in the form of a patch.